Skip to main content
. 2022 Oct 7;14(10):2131. doi: 10.3390/pharmaceutics14102131

Figure 6.

Figure 6

Figure 6

Antitumor efficacy and safety of FRRG-MMAE nanoparticles in breast tumor-bearing mice. (a) Tumor growth of 4T1 tumor-bearing mice during treatment with free MMAE or FRRG-MMAE nanoparticles once every three days. (b) Tumor tissues stained with fluorescent dye Cy5.5-conjugated tubulin antibody after 5 days of treatment. (c) Tumor and organ tissues stained with H&E after 5 days of treatment with free MMAE or FRRG-MMAE nanoparticles. (d) Hematological parameters of mice treated with saline, free MMAE or FRRG-MMAE for 5 days. (e) The body weight of mice during treatment with free MMAE or FRRG-MMAE nanoparticles once every three days. (f) The mice survival. The statistical significance was indicated with asterisks *** p < 0.001 in the figures.